Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 57 Carcinoma, Hepatocellular 45 Lung Neoplasms 27 Breast Neoplasms 26 Small Cell Lung Carcinoma 17 Neoplasms 17 Triple Negative Breast Neoplasms 16 Neoplasm Metastasis 16 Carcinoma, Transitional Cell 13 Melanoma 12 Colorectal Neoplasms 12 Urinary Bladder Neoplasms 11 Prostatic Neoplasms 9 Head and Neck Neoplasms 9 Recurrence 8 Ovarian Neoplasms 8 Liver Neoplasms 7 Glioblastoma 7 Mesothelioma, Malignant 6 Endometrial Neoplasms 6 Carcinoma, Renal Cell 6 Sarcoma 5 Rectal Neoplasms 5 Gastrointestinal Neoplasms 5 Carcinoma, Squamous Cell 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 4 Kidney Neoplasms 4

Interventions

nimotuzumab 1 atezolizumab 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡